Veronica Miller1, Jude Nwokike, Andy Stergachis. 1. Forum for Collaborative HIV Research, School of Public Health, University of California Berkeley, USA. veronicam@berkeley.edu
Abstract
PURPOSE OF REVIEW: This review focuses on current status, progress, challenges and opportunities in global pharmacovigilance for HIV/AIDS treatment. RECENT FINDINGS: Over 6 million HIV-infected individuals worldwide are on treatment with more than 150 innovator and generic antiretroviral drug products. This achievement is made possible through sponsorship of HIV/AIDS programs [The Global Fund to Fight AIDS, Tuberculosis and Malaria; the President's Emergency Program for AIDS Relief (PEPFAR)] and the availability of generic fixed-dose combination products. The WHO prequalifies generic drug products used by Global Fund programs; the US Food and Drug Administration tentatively approves generic products used by PEPFAR programs through a fast-track review process. Adequate national or regional quality and safety monitoring systems after drug distribution are lacking. The pharmaceutical sector, a significant player in pharmacovigilance in the developed world, has not been engaged. Innovative approaches based on collaboration and partnerships will be needed. Clinic-based or program-based cohort studies, randomized clinical trials and electronic medical records may contribute pharmacovigilance-relevant information. SUMMARY: Attention to drug quality and safety is obligatory for long-term program sustainability. Systematic approaches to regional pharmacovigilance that make use of diverse data sources, and collaborative partnerships between industry, clinical and/or research programs and national health authorities can potentially contribute to overall health system strengthening.
PURPOSE OF REVIEW: This review focuses on current status, progress, challenges and opportunities in global pharmacovigilance for HIV/AIDS treatment. RECENT FINDINGS: Over 6 million HIV-infected individuals worldwide are on treatment with more than 150 innovator and generic antiretroviral drug products. This achievement is made possible through sponsorship of HIV/AIDS programs [The Global Fund to Fight AIDS, Tuberculosis and Malaria; the President's Emergency Program for AIDS Relief (PEPFAR)] and the availability of generic fixed-dose combination products. The WHO prequalifies generic drug products used by Global Fund programs; the US Food and Drug Administration tentatively approves generic products used by PEPFAR programs through a fast-track review process. Adequate national or regional quality and safety monitoring systems after drug distribution are lacking. The pharmaceutical sector, a significant player in pharmacovigilance in the developed world, has not been engaged. Innovative approaches based on collaboration and partnerships will be needed. Clinic-based or program-based cohort studies, randomized clinical trials and electronic medical records may contribute pharmacovigilance-relevant information. SUMMARY: Attention to drug quality and safety is obligatory for long-term program sustainability. Systematic approaches to regional pharmacovigilance that make use of diverse data sources, and collaborative partnerships between industry, clinical and/or research programs and national health authorities can potentially contribute to overall health system strengthening.
Authors: Marita Mann; Assegid Mengistu; Johannes Gaeseb; Evans Sagwa; Greatjoy Mazibuko; Joseph B Babigumira; Louis P Garrison; Andy Stergachis Journal: Drug Saf Date: 2016-09 Impact factor: 5.606
Authors: Mukhtar A Adeiza; Ian Wachekwa; Cecilia Nuta; Sean Donato; Freda Koomson; Jane Whitney; Chelsea Plyler; Lila Kerr; Godsway Sackey; Elizabeth Dunbar; Kristina Talbert-Slagle; Robin Klar; Regan H Marsh; Samretta Caldwell; Julia Toomey; Onyema Ogbuagu Journal: Ann Glob Health Date: 2021-11-24 Impact factor: 2.462
Authors: Reneé de Waal; Karen Cohen; Andrew Boulle; Matthew P Fox; Gary Maartens; Ehimario U Igumbor; Mary-Ann Davies Journal: PLoS One Date: 2018-09-05 Impact factor: 3.240